›› 2014, Vol. 29 ›› Issue (5): 574-575.DOI: 10.3969/j.issn.1673-8640.2014.05.032
Previous Articles Next Articles
Received:2013-11-01
Online:2014-05-30
Published:2014-05-27
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2014.05.032
| [1] Ognsawara K, Mashiba S, Wads Y, et al.A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease[J].Atheroselerosis, 2004, 174(2):349-356. [2] 刘 钢, 王兰兰, 李立新, 等.血清淀粉样蛋白A——类风湿关节炎的一个炎性指标[J].中华风湿病学杂志, 2002, 6(2):108-110. [3] 陈长强, 顾志冬, 樊绮诗. 血清淀粉样蛋白A在疾病应用中的研究进展[J]. 检验医学, 2012, 27(9): 776-779. [4] 吴海云, 王士雯, 朱 姝, 等.川芎嗪在急性冠状动脉综台征中抗炎作用的研究[J].中国中西医结合急救杂志, 2004, 11(4) :196-198. [5] Vuilleumier N, Reber G, James R, et al.Presence of autoantibodies to apolipoptotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease[J].J Auteimmun, 2004, 23(4):353-360. [6] 洪 华, 传良敏, 袁 红, 等. 川崎病患儿血清淀粉样蛋白A的测定及临床意义[J]. 检验医学, 2005, 20(6): 524-525. [7] Uhlar CM, Whitehead AS.Serum amyloid A, the major vertebrate acute-phase reactant[J].Eur J Biochem, 1999, 265(2):501-523. [8] 陈长强, 杨 晶, 顾志冬, 等. 斑点免疫金渗滤法定量测定血清淀粉样蛋白A方法的建立及性能评估[J]. 检验医学, 2013, 28(9): 835-840. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
